[Breaking] J&J "Janssen Vaccine Shows Strong Immune Efficacy Against Delta Variant"
![[Breaking] J&J "Janssen Vaccine Shows Strong Immune Efficacy Against Delta Variant"](http://www.asiae.co.kr/news/img_view.htm?img=2021061808010985412_1623970870.png)
[Asia Economy Reporter Kim Suhwan] The Janssen COVID-19 vaccine from the U.S. pharmaceutical company Johnson & Johnson (J&J) has demonstrated strong immune efficacy against the Delta variant, maintaining immune protection for over eight months after completing vaccination.
Hot Picks Today
Dramatic Agreement Reached on Eve of Samsung Electronics General Strike... Minister Kim Young-hoon: "Showcased Korea's Strength in Dialogue" (Update)
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- Japanese Courts Reduce Paperwork, Ushering in Full-Fledged Era of Electronic Civil Litigation
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
On the 1st (local time), J&J issued a statement announcing that its Janssen vaccine possesses powerful immune efficacy capable of neutralizing the Delta variant. The company also added that this effect is achieved with the existing vaccine regimen alone, without the need for a booster shot intended to enhance immune efficacy.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
